Dark

Check out our API

VTYX
Ventyx Biosciences, Inc. Common Stock
stock NASDAQ

Market Open

Dec 8, 2025 11:41:55 AM EST

8.91USD+2.179%(+0.19)795,826

8.88Bid 8.92Ask 0.04Spread

Pre-market

Dec 5, 2025 9:25:30 AM EST

8.00USD-8.257%(-0.72)0

After-hours

Dec 5, 2025 4:00:30 PM EST

8.72USD-0.115%(-0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Dec 6, 2021

08:03AM EST Ventyx Biosciences Announces First Patient Dosed In Phase 2 Clinical Trial Of VTX002 For Treatment Of Moderate-To-Severe Ulcerative Colitis Benzinga

08:00AM EST Ventyx Biosciences Announces First Patient Dosed in a Phase 2 GlobeNewswire Inc

Nov 19, 2021

08:00AM EST Ventyx Biosciences, Inc. (Nasdaq: VTYX), (Ventyx or the Company), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the following upcoming investor conferences: GlobeNewswire Inc

Nov 17, 2021

04:19PM EST Ventyx Biosciences Q3 EPS $(3.17) Up From $(3.58) YoY Benzinga

04:11PM EST Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets GlobeNewswire Inc

Nov 15, 2021

11:20AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021 Benzinga

11:11AM EST Evercore ISI Group Initiates Coverage On Ventyx Biosciences with Outperform Rating, Announces Price Target of $50 Benzinga

10:52AM EST Jefferies Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $30 Benzinga

10:46AM EST Piper Sandler Initiates Coverage On Ventyx Biosciences with Overweight Rating, Announces Price Target of $50 Benzinga

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

Oct 25, 2021

04:59PM EDT Ventyx Biosciences Announces Closing of Upsized Initial Public GlobeNewswire Inc

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 21, 2021

12:12PM EDT Ventyx Biosciences Shares Open For Trade At $18.65; IPO Priced At $16/Share Benzinga

12:12PM EDT Several IPOs Expected For Thursday, Including: Portillo's (PTLO), Enfusion (ENFN), Runway Growth Finance (RWAY), Ventyx Biosciences (VTYX), The Vita Coco Co. (COCO) Benzinga

12:12PM EDT Ventyx Biosciences Shares To Open For Quote At 11 a.m. EDT, Expected To Open For Trade After 11:10 a.m.; IPO Priced At $16/Share Benzinga

12:11PM EDT The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO Benzinga

Sep 20, 2021

05:00AM EDT -- Drs. Sheila Gujrathi (Executive Chair), Jrn Drappa (Chief Medical Officer) and Luisa Salter-Cid (Chair of the Scientific Advisory Board) bring decades of development experience in autoimmune diseases -- William White (Independent Director) strengthens financial and business acumen of Ventyx board -- Proceeds will further accelerate development of clinical programs GlobeNewswire Inc

Share